Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.54 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | RAC1 | P63000 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PTGIR | P43119 | 1/20 | 0.40 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.40 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4046578 | 0.87 | MMP13 (0.51) | CHRNA4RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL3450856 | 0.83 | MMP13 (0.52) | CHRNA4RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4048304 | 0.83 | RAB9A (0.43) | RAB9ANPC1PDE4BCHRNA7 | |
| SCHEMBL4047832 | 0.80 | CHRNA7 (0.61) | SMN1; SMN2CHRNA7 | |
| SCHEMBL3327886 | 0.78 | NQO2 (0.53) | NQO2PDE5ARAC1RAB9ASMN1; SMN2 | |
| SCHEMBL6264880 | 0.76 | NQO2 (0.76) | NQO2RAC1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4050262 | 0.75 | RAB9A (0.52) | RAB9ASMN1; SMN2NPC1PDE4B | |
| SCHEMBL5606200 | 0.75 | NQO2 (0.70) | NQO2RAC1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4047306 | 0.74 | RAB9A (0.44) | RAB9ANPC1 | |
| SCHEMBL4198288 | 0.73 | ALDH1A1 (0.59) | NQO2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612074-B2 | Diazabicyclic aryl derivatives as cholinergy ligands | NEUROSEARCH A/S (DK) | 2009-11-03 | — | — | US | claimed |
| EP-1819709-B1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGY LIGANDS | NEUROSEARCH AS (DK) | 2009-02-11 | — | — | EP | claimed |
| US-20070265271-A1 | Novel Diazabicyclic Aryl Derivatives as Cholinergy Ligands | NEUROSEARCH A/S (DK) | 2007-11-15 | — | — | US | claimed |
| US-7612074-B2 | Diazabicyclic aryl derivatives as cholinergy ligands | NEUROSEARCH A/S (DK) | 2009-11-03 | — | — | US | disclosed |
| EP-1819709-B1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGY LIGANDS | NEUROSEARCH AS (DK) | 2009-02-11 | — | — | EP | disclosed |
| US-20070265271-A1 | Novel Diazabicyclic Aryl Derivatives as Cholinergy Ligands | NEUROSEARCH A/S (DK) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265271-A1 | Novel Diazabicyclic Aryl Derivatives as Cholinergy Ligands | CHRNA6, CHRNA10, CHRNA2 | NQO2 2173/4885PDE5A 494/4885RAC1 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.